SCHEMBL1865083

SCHEMBL1865083

CC(C)OC(=O)C1=CC2(CCC1S(=O)(=O)Nc1ccc(F)cc1Cl)OCCO2

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 5/20 0.51
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 1/20 0.34
LMNA P02545 2/20 0.34
TP53 P04637 1/20 0.34
MRGPRX1 Q96LB2 3/20 0.33
MGLL Q99685 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
NPY1R P25929 1/20 0.32
NPY2R P49146 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HRH1 P35367 1/20 0.31
TSPO P30536 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1870814 0.91 TLR4 (0.55) TLR4ALDH1A1GAAKMT2ANPC1
SCHEMBL1866373 0.88 TLR4 (0.51) TLR4ALDH1A1GAAKMT2ANPC1
SCHEMBL1863576 0.88 TLR4 (0.68) TLR4ALDH1A1GAAKMT2ALMNA
SCHEMBL1863038 0.86 TLR4 (0.59) TLR4ALDH1A1GAAKMT2ANPC1
SCHEMBL1867598 0.86 TLR4 (0.56) TLR4ALDH1A1GAAKMT2ANPC1
SCHEMBL1865788 0.86 TLR4 (0.50) TLR4ALDH1A1GAAKMT2ANPC1
SCHEMBL1866183 0.85 TLR4 (0.57) TLR4ALDH1A1GAAKMT2ANPC1
SCHEMBL1862070 0.84 TLR4 (0.67) TLR4KMT2ALMNAMRGPRX1NPSR1
SCHEMBL1869385 0.84 TLR4 (0.67) TLR4ALDH1A1KMT2ALMNAMRGPRX1
SCHEMBL17727730 0.83 TLR4 (0.53) TLR4ALDH1A1GAAKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43858-E1 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-7935835-B2 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-7935835-B2 Substituted cycloalkene derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-05-03 US disclosed
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1935879-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2008-06-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233952-A1 SUBSTITUTED CYCLOALKENE DERIVATIVE CD40, LITAF, TNF TLR4 29/4885ALDH1A1 4252/4885GAA 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.